RPL22P18

Across TCGA pan-cancer cohorts, RPL22P18 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated RPL22P18 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RPL22P18 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL22P18 expression acts as an unfavorable survival marker, although some lineages such as TGCT and CHOL show a favorable association.

ACC, KIRC, and PAAD are the cancer types where RPL22P18 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Tertile	III,IV	0.066	0.517	<.001	138	view →
KIRC	DFS	Tertile	IV	0.316	0.573	.001	62	view →
PAAD	OS	Tertile	All	0.492	0.655	.006	42	view →
KIRP	DFS	Tertile	IV	0.154	0.548	<.001	39	view →
KICH	DFS	Tertile	All	0.559	0.909	.007	36	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
LIHC	DFS	Tertile	III,IV	0.079	0.438	<.001	21	view →
TGCT	DFS	Tertile	All	1.000	0.591	.001	18	view →
STAD	DFS	Quartile	III,IV	0.555	0.760	.018	15	view →
CHOL	OS	Tertile	All	1.000	0.503	.013	15	view →
COAD	OS	Tertile	All	0.732	0.501	.011	13	view →
CESC	OS	Tertile	All	0.882	0.759	.017	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

RPL22P18–ACC (DFS)

Open the ACC breakdown →